UK-based clinical-stage biotechnology company TC BioPharm (Holdings) PLC (NASDAQ:TCBP) announced on Monday shareholder approval of a 25% stock dividend during its General Meeting.
The special dividend grants 0.25 American Depositary Shares (ADSs) for each ADS held on the record date of 2 January 2025, with delivery anticipated by 6 January 2025.
Trading in TC BioPharm's ADSs will pause at 17:00 hours on 2 January 2025, per Nasdaq requirements, resuming around 8 January 2025, to facilitate the dividend process. Nasdaq plans to adjust the opening price on 8 January to account for dilution from the dividend issuance.
L'Oréal and WHO Foundation partner to expand global skin health access
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
ANI Pharmaceuticals announces buyout of royalty obligation for ILUVIEN and YUTIQ
Sirum collaborates with Governor Wes Moore to expand medication access across Maryland
Abbott announces quarterly common dividend
West Pharmaceutical Services announces Q2 dividend
Perrigo increases quarterly dividend
AbbVie announces quarterly cash dividend
hVIVO acquires German Clinical Research Units for EUR10m; Targets earnings growth by 2026
OptiBiotix expands into Indian market with Amazon launch
Poxel to receive royalties and sales-based payment from Sumitomo Pharma
ReciBioPharm secures grant to expand RNA manufacturing in LMICs
CVS Health to pays common stock quarterly dividend of USD0.665 per share
TC BioPharm receives shareholders' approval for 25% stock dividend